Discover
ELDN
Eledon Pharmaceuticals, Inc.
3.90
2 x 2.93
2 x 4.94
bid
ask
-
0.04
1.02%
2 @ 05:44 AM
4.11 +0.21 (5.38%)
| Ytd | 158.28% | |
| 1y | 39.78% |
3.85
day range
4.09
1.35
52 week range
4.60
| Open | 3.95 | Prev Close | 3.94 | Low | 3.85 | High | 4.09 | Mkt Cap | 301.03M |
| Vol | 1.62M | Avg Vol | 1.53M | EPS | -0.77 | P/E | N/A | Forward P/E | -3.49 |
| Beta | 0.77 | Short Ratio | 0.75 | Inst. Own | 42.88% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 3.72 | 200-d Avg | 2.78 | 1yr Est | 12.50 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-12 | 2024-09 | -0.3 | -0.32 | -0.02 | -6.67% |
| 2024-08-19 | 2024-06 | -0.31 | -0.32 | -0.01 | -3.23% |
| 2024-05-09 | 2024-03 | -0.37 | -0.34 | 0.03 | 8.11% |
| 2024-03-28 | 2023-12 | -0.38 | -0.29 | 0.09 | 23.68% |
| 2023-11-09 | 2023-09 | -0.41 | -0.35 | 0.06 | 14.63% |
| 2023-08-10 | 2023-06 | -0.47 | -0.4 | 0.07 | 14.89% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-20 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-06-04 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-05-10 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-05-07 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-03-22 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2023-11-13 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for kidney transplantation, xenotransplantation, and liver transplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-05-08 | BVF PARTNERS L P | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | BVF Inc. | 6.29M | 26.37M | 10.53% |
| 2024-09-29 | Armistice Capital, LLC | 2.36M | 9.91M | 3.96% |
| 2024-09-29 | Vanguard Group Inc | 1.57M | 6.56M | 2.62% |
| 2024-09-29 | Schonfeld Strategic Advisors Llc | 1.50M | 6.29M | 2.51% |
| 2024-09-29 | Zimmer Partners, Lp | 1.43M | 6.01M | 2.40% |
| 2024-09-29 | Sphera Funds Management Ltd. | 1.30M | 5.44M | 2.17% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 1.15M | 4.83M | 1.93% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 385.14K | 1.61M | 0.64% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 220.43K | 923.61K | 0.37% |
| 2024-10-30 | iShares Micro Cap ETF | 87.89K | 368.28K | 0.15% |
| 2024-10-30 | Fidelity Total Market Index Fund | 56.62K | 237.23K | 0.09% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 48.88K | 204.80K | 0.08% |
Split
| Split | Date |
|---|---|
| 1 : 18 | 2020-10-05 |
| 1 : 9 | 2017-05-11 |